The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US ...

Danish CNS company Lundbeck announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness ...

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) has priced an $850 million offering of 5.5% senior unsecured notes due 2034 ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

US biotech major Regeneron (Nasdaq: REGN) has presented its financial results for the fourth quarter and full year 2025.

UK pharma major AstraZeneca is strengthening its weight management portfolio through a new strategic collaboration agreement ...

Belgian biotech Agomab Therapeutics has set the terms for its planned US initial public offering, according to a filing with ...

Privately-held Swedish neuropathic pain specialist PharmNovo has announced changes to its board of directors, welcoming two ...

Germany-based Vetter Pharma has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.

The US Food and Drug Administration has accepted Summit Therapeutics’ (Nasdaq: SMMT) application for ivonescimab plus ...

South Korea’s Samsung Bioepis says it has signed a settlement and license agreement with Regeneron and Bayer concerning the commercialization of SB15, a biosimilar to Eylea 2mg (aflibercept 40mg/mL ...

US ophthalmology company SpyGlass Pharma has set out the terms of an initial public offering (IPO) in which the firms hopes ...